Table 1.
Baseline Characteristics of the Study Population (AML patients, N = 90).
| Parameters | N | Percent | |
|---|---|---|---|
| Age groups | <15 Years | 3 | 3.3 |
| 15–40 Years | 62 | 68.9 | |
| 41–60 Years | 24 | 26.7 | |
| >60 Years | 1 | 1.1 | |
| Gender | Male | 66 | 73.3 |
| Female | 24 | 26.7 | |
| AML classification (who) | APL (M3) with t 15:17 | 17 | 18.9 |
| AML without maturation (M1) | 15 | 16.7 | |
| AML with maturation (M2) | 44 | 48.9 | |
| Others: | 8 | 8.9 | |
| -Translocation 6:9 | 2 | 2.2 | |
| -AML with minimal differentiation (M0) | 2 | 2.2 | |
| -Acute Myelomonocytic Leukemia (M4) | 2 | 2.2 | |
| -Acute Panmyelosis with fibrosis | 1 | 1.1 | |
| -Myeloid proliferations related to Down syndrome | 1 | 1.1 | |
| Unknown | 6 | 6.7 | |
| MPO status | Negative | 14 | 15.6 |
| Positive | 62 | 68.9 | |
| Unknown | 14 | 15.6 | |
| FLT3 mutation | Negative | 35 | 38.9 |
| Positive | 7 | 7.8 | |
| Unknown | 48 | 53.3 | |
| NPM1 mutation | Negative | 13 | 14.4 |
| Unknown | 77 | 85.6 | |
| PML-RAR mutation | Negative | 4 | 4.4 |
| Positive | 5 | 5.6 | |
| Unknown | 81 | 90.0 | |
| MLL mutation | Negative | 10 | 11.1 |
| Positive | 5 | 5.6 | |
| Unknown | 75 | 83.3 | |
| Karyotyping | Unfavorable | 18 | 20.0 |
| Favorable (APL) | 7 | 7.8 | |
| Normal | 24 | 26.7 | |
| Unknown | 41 | 45.6 | |
| Therapeutic response | Resistant | 34 | 37.8 |
| Relapse | 19 | 21.1 | |
| Persistant Remission | 37 | 41.1 | |
| Survival status | Died | 42 | 46.7 |
| Alive | 44 | 48.9 | |
| Unknown | 4 | 4.4 | |
| Final outcome | Poor (Resistant + Relapse) | 53 | 58.9 |
| Good (Persistent Remission) | 37 | 41.1 | |